Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation
Authors:
- 6 December 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 4 (1) , 113-117
Abstract
Potent imidazopyridine-based inhibitors of fatty acid synthase (FASN) are described. The compounds are shown to have antiviral (HCV replicon) activities that track with their biochemical activities. The most potent analogue (compound 19) also inhibits rat FASN and inhibits de novo palmitate synthesis in vitro (cell-based) as well as in vivo.Keywords
This publication has 22 references indexed in Scilit:
- Systematic Approaches towards the Development of Host-Directed Antiviral TherapeuticsInternational Journal of Molecular Sciences, 2011
- Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetesProceedings of the National Academy of Sciences, 2011
- Hepatitis C — pipeline updateNature Reviews Drug Discovery, 2011
- Fatty Acid Synthase As a Potential Therapeutic Target in CancerFuture Oncology, 2010
- Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysisBioorganic & Medicinal Chemistry Letters, 2009
- Fatty acid metabolism: target for metabolic syndromeJournal of Lipid Research, 2009
- Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and productionHepatology, 2008
- Host-Directed Drug Targeting of Factors Hijacked by PathogensScience Signaling, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Optimization of Monocarboxylate Transporter 1 Blockers through Analysis and Modulation of Atropisomer Interconversion PropertiesJournal of Medicinal Chemistry, 2006